Influence of Emergence of Viral Resistance on HIV Treatment Choice

Valian R Moyle G Reddy D. Physician decision-making in antiretroviral use. Br J Clin Pruct 1994;48:241–3.

Abrams DI Goldman AI Launer C A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency syndrome. N Engl J Med 1994;330:657–62.

Larder B Darby B Richman D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4.

Rooke R Tremblay M Soudeyns H Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989;3:411–5.

Rooke R Parniak MA Tremblay M Biological comparisons of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: Susceptibility and resistance to other drugs. Antimicrob Agents Chemother 1991;35:988–91.

Fischl M Collier A Stanley K The safety and efficacy of zidovudine (ZDV) and zalcitabine (ddC) or ddC alone versus ZDV. IXth International Conference on AIDS. Berlin, June 1993 [abstract WS-B25–1].

Yarchoan R Leitzau JA Nguyen B-Y A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:9–17.

Fitzgibbon JE Farnham AE Sperber SJ Kim H Dubin DT. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol 1993;67:7271–5.

Richman DD Meng TC Spector SA Fischl MA Resnick L Lai S. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:135–8.

Eron JJ Johnson VA Merrill DP Chou T-C Hirsch MS. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate by zidovudine and 2′,3′-dideoxycytidine in vitro . Antimicrob Agents Chemother 1992;36:1559–652.

Johnson VA Merrill DP Videler JA Two-drug combinations of zidovudine, didanosine and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type-1 synergistically in vitro . J Infect Dis 1991;164:646–55.

Meng T-C Fischl MA Boota AM Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116:13–20.

Collier AC Coombes RW Fischl MA Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786–93.

Conway B Ko D Marshall L Evaluation of ddC susceptibility in patients on AZT or ddI. 2nd International HIV Drug Resistance Workshop. Noordwijk, June 1993 [abstract].

St Clair MH Martin JL Tudor-Williams G Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557–9.

Gu Z Gao Q Li X Parniak MA Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992;66:7128–35.

Gao Q Gu Z Parniak MA The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:1390–2.

Fitzgibbon JE Howell RM Haberzettl C Sperber SJ Gocke DJ Dubin DT. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptiblity to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992;36:153–7.

Gu Z Gao Q Fang H Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994;38:275–81.

Zhang D Caliendo AM Eron JJ Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994;38:282–7.

Montaner JSG Singer J Schechter MR Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZT trial. AIDS 1993;7:189–96.

St Clair MH Hartigan PM Andrews JC Zidovudine resistance, syncytium-inducing phenotype and HIV disease progression in a case control study. J Acquir Immune Defic Syndr 1993;6:891–7.

Ogino MT Danker WM Spector SA : Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Paediatr 1993;123:1–8.